reports
- Alexander Aukner
LSG LEROY SEAFOOD GROUP ASA
AUSS AUSTEVOLL SEAFOOD ASA
AKVA AKVA GROUP ASA
SALM SALMAR ASA
GSF GRIEG SEAFOOD ASA
MOWI MOWI ASA
BAKKA BAKKAFROST P/F
SALMOCAM SALMONES CAMANCHACA SA
IFISH ICE FISH FARM AS
ASA ATLANTIC SAPPHIRE
SALME SALMON EVOLUTION HOLDING
KING THE KINGFISH COMPANY NV
AKBM AKER BIOMARINE
ISLAX ARNARLAX AS
AFISH ARCTIC FISH HOLDING AS
MAS MÅSØVAL
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Eval...
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Media ReleaseCOPENHAGEN, Denmark; September 3, 2025 Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in an outpatient setting Results showed that 92% of patients with R/R DLBCL received the first full dose of epcoritamab monotherapy in an outpatient settingAdverse event profile and efficacy...
- Alexander Aukner
LSG LEROY SEAFOOD GROUP ASA
AUSS AUSTEVOLL SEAFOOD ASA
AKVA AKVA GROUP ASA
SALM SALMAR ASA
GSF GRIEG SEAFOOD ASA
MOWI MOWI ASA
BAKKA BAKKAFROST P/F
SALMOCAM SALMONES CAMANCHACA SA
IFISH ICE FISH FARM AS
ASA ATLANTIC SAPPHIRE
SALME SALMON EVOLUTION HOLDING
KING THE KINGFISH COMPANY NV
AKBM AKER BIOMARINE
ISLAX ARNARLAX AS
AFISH ARCTIC FISH HOLDING AS
MAS MÅSØVAL
- Alexander Aukner
Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd An...
Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; August 26, 2025 (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York City, NY at 7:45 AM EDT (1:45 PM CEST) on September 9, 2025. A webcast of the fireside chat will be available on Genmab’s website at . About Genmab Genmab is an international biotechnology company with a co...
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Se...
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) Media ReleaseCOPENHAGEN, Denmark; August 26, 2025 Breakthrough Therapy Designation granted to Rina-S for the treatment of adult patients with recurrent or progressive endometrial cancer (EC) who have disease progression on or following prior treatment with a platinum-containing regimen and a PD-(L)1 therapyRegulatory decision supported by data from the Phase 1/2 RAINFOL™-01 trial showing encouraging responses in heavily pretreated EC patientsiRina-S continues to be ev...
- ABGSC Seafood Research
- Martin Kaland
- Oliver Dunvold
- Simon Brun
- ABGSC Seafood Research
- Martin Kaland
- Oliver Dunvold
- Simon Brun
Mowi ASA (OSE: MOWI): Quarterly dividend
Mowi ASA (OSE: MOWI): Quarterly dividend The Board of Mowi ASA has resolved on 19 August 2025 to make a quarterly distribution to shareholders of NOK 1.45 per share. Mowi ASA’s shares listed on the Oslo Stock Exchange will be traded including dividend up to and including 28 August 2025. Mowi ASA’s shares listed on the Oslo Stock Exchange will be traded excluding dividend from and including 29 August 2025. Mowi ASA’s shares listed on the Oslo Stock Exchange will have a Record Date of 1 September 2025. The expected payment date is 8 September 2025. This information is subject to the disclos...
Seasonally record-high volumes and revenues for Mowi in Q2
Seasonally record-high volumes and revenues for Mowi in Q2 (Bergen, 20 August 2025) Mowi generated operating revenues of EUR 1.39 billion in the second quarter which translated into an operational profit of EUR 189 million. The second quarter of 2025 ended with record-high revenues for Mowi, on strong biological and operational performance, all-time high volumes and decreasing cost. “2025 has so far been a good year for the Farming division with very good operations and strong growth,” said Mowi CEO, Ivan Vindheim. Mowi harvested a record 133,000 tonnes in the second quarter, representin...
Rekordhøye andrekvartalsvolumer og -inntekter for Mowi
Rekordhøye andrekvartalsvolumer og -inntekter for Mowi (Bergen, 20. august 2025) Mowi rapporterte inntekter på 1,39 milliarder euro (16,29 milliarder kroner) og et operasjonelt driftsresultat på 189 millioner euro (2,20 milliarder kroner) i andre kvartal. Andre kvartal endte med rekordhøye inntekter for Mowi for denne delen av året, som følge av sterk biologisk og operasjonell drift, rekordhøye volumer og lavere kostnader. – 2025 har vært et godt år med meget god drift og sterk vekst så langt for havbruksvirksomheten, sier konsernsjef i Mowi, Ivan Vindheim. Mowi slaktet rekordhøye 133 00...
- ABGSC Seafood Research
- Martin Kaland
- Oliver Dunvold
- Simon Brun
- ABGSC Seafood Research
- Martin Kaland
- Oliver Dunvold
- Simon Brun
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; August 12, 2025 – (Nasdaq: GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,580 shares at DKK 1,025.00,1,874 shares at DKK 1,050.00, and109 shares at DKK 1,161.00. Proceeds to the company are approximately DKK 4.7 million....
Mowi ASA (OSE:MOWI): Presentation of Q2 2025 results 20 August 2025 at...
Mowi ASA (OSE:MOWI): Presentation of Q2 2025 results 20 August 2025 at 08:00 (CET) Mowi ASA hereby invites you to the presentation of the results for the second quarter 2025 at Scandic Flesland Airport hotel in Bergen, Norway in connection with the event “Vestland på Børs”. The results will be presented in English through a live webcast followed by a Q&A session. Participants will have the opportunity to submit questions online throughout the webcast session. The webcast will be available on A recording of the webcast will be made available on our website immediately afterwards. Please ...
Genmab Announces Financial Results for the First Half of 2025
Genmab Announces Financial Results for the First Half of 2025 August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab advancing to earlier lines of therapy with the submission of a sBLA to the FDA for epcoritamab plus R2 in patients with relapsed or refractory FLRinatabart sesutecan (Rina-S®) continues to progress, demonstrating encouraging antitumor activity in endometrial cancer in data presented at the 2025 ASCO Annual MeetingData from over 40 abstracts highlighting the depth, breadth and strength of Genmab’s comprehensive epcori...
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary ...
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Company Announcement COPENHAGEN, Denmark; August 7, 2025 Epcoritamab in combination with rituximab and lenalidomide (R2) demonstrated statistically significant improvement in Overall Response Rate (ORR; 95.7%, p < 0.0001) and Progression-Free Survival (HR 0.21, p-value
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quart...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025 Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 16, 2025 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,5...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.